Literature DB >> 8087933

Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty.

D P Foley1, R Melkert, P W Serruys.   

Abstract

BACKGROUND: Although coronary angioplasty is increasingly applied in the treatment of multivessel disease and a broadening range of vessel size, the influence of vessel size itself on the late results of intervention is unresolved. An influence of vessel size on late outcome would carry implications for the application and evaluation of interventional devices, which are selectively used in larger or smaller vessels. The purpose of the present study was to investigate the influence of vessel size on both the restenosis process and late angiographic outcome in a large homogeneous patient group after successful percutaneous transluminal coronary angioplasty (PTCA). METHODS AND
RESULTS: The study population comprised 3072 patients with 3736 successfully dilated native primary coronary artery lesions and satisfactory quantitative angiographic analysis in multiple identical projections before and after PTCA and at a 6-month follow-up. Late luminal loss, minimal luminal diameter (MLD) at follow-up, and net luminal gain, as well as percent diameter stenosis at follow-up, net gain in percent diameter stenosis, restenosis rates (according to three definitions), and net gain index, were all compared among nine equally sized groups (noniles) according to vessel size. A direct influence of vessel size on continuous measures of late result was also evaluated by linear regression. These evaluations provided conflicting information with no consistent influence of vessel size emerging. To elucidate the independent influence of vessel size on the restenosis process (late loss) and late angiographic outcome (MLD at follow-up), multiple linear regression analysis was performed taking into account luminal gain, preprocedural MLD, and lesion location. In this manner, vessel size was found to be exert a significantly positive influence on MLD at follow-up (P < .0001) and an equally negative effect on loss. Correcting for vessel size by using percent stenosis measurements led to an anticipated neutralization of this influence. Lesion location in the left anterior descending coronary artery was found to be independently associated with greater loss and smaller MLD at follow-up (P < .0001).
CONCLUSIONS: Increasing coronary vessel size was found to be independently predictive of decreasing late luminal loss and increasing follow-up MLD after successful balloon angioplasty. Apparently superior or inferior late angiographic results of new interventional devices may thus be explained in part by preferential use in larger or smaller vessels, respectively. Devices that can safely optimize the short-term result of intervention may realize their ultimate long-term value in larger coronary vessels.

Entities:  

Mesh:

Year:  1994        PMID: 8087933     DOI: 10.1161/01.cir.90.3.1239

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Early lumen diameter loss after percutaneous transluminal coronary angioplasty is related to coronary plaque burden: a role for viscous plaque properties in early lumen diameter loss.

Authors:  W E Kok; R J Peters; G Pasterkamp; R A van Liebergen; J J Piek; K T Koch; C A Visser
Journal:  Int J Cardiovasc Imaging       Date:  2001-04       Impact factor: 2.357

2.  Angiographic segment size in patients referred for coronary intervention is influenced by constitutional, anatomical, and clinical features.

Authors:  Pedro A Lemos; Expedito E Ribeiro; Marco A Perin; Luiz J Kajita; Marco A de Magalhães; João L A A Falcão; Antonio Esteves Filho; Marcus N da Gama; Pedro E Horta; Gilberto G Marchiori; Andre G Spadaro; Eulógio E Martinez
Journal:  Int J Cardiovasc Imaging       Date:  2006-06-30       Impact factor: 2.357

3.  Effects of age on aortic blood velocity at rest and during exercise in patients with coronary artery disease.

Authors:  A M Salmasi; C Dorĕ; M Dancy
Journal:  Clin Auton Res       Date:  1996-04       Impact factor: 4.435

4.  Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS).

Authors:  Man-Hong Jim; Kai-Hang Yiu; Raymond Chi-Yan Fung; Hee-Hwa Ho; Andrew Kei-Yan Ng; Chung-Wah Siu; Wing-Hing Chow
Journal:  Heart Vessels       Date:  2013-02-24       Impact factor: 2.037

5.  Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry.

Authors:  Shailja V Parikh; Michael Luna; Faith Selzer; Oscar C Marroquin; Suresh R Mulukutla; J Dawn Abbott; Elizabeth M Holper
Journal:  Catheter Cardiovasc Interv       Date:  2013-10-24       Impact factor: 2.692

Review 6.  "Obesity paradox" in coronary artery disease.

Authors:  Ibrahim Akin; Christoph A Nienaber
Journal:  World J Cardiol       Date:  2015-10-26

7.  Clinical and angiographic outcome in patients with in-stent restenosis and repeat target lesion revascularisation in small coronary arteries.

Authors:  C M Gross; J Krämer; O Weingärtner; F Uhlich; R Dietz; J Waigand
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

8.  Influence of a history of smoking on short term (six month) clinical and angiographic outcome after successful coronary angioplasty.

Authors:  A G Violaris; A Thury; E Regar; R Melkert; P W Serruys
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

9.  Utilization of self-expanding stents in the treatment of intracranial atherosclerotic disease in the distal small cerebral vessels.

Authors:  Aquilla S Turk; Azam Ahmed; David B Niemann; Beverly Aagaard-Kienitz; Nathaniel Brooks; Ross L Levine
Journal:  Neuroradiology       Date:  2007-03-27       Impact factor: 2.804

10.  Long-Term Clinical Outcomes of New-Generation Drug-Eluting Stents in Coronary Artery Disease: A Real-World Observational Study.

Authors:  Hsun-Hao Chang; Chi-Feng Hung; I-Chih Chen; Po-Ching Wu; Li-Wei Liu; Ching-Chang Fang
Journal:  Acta Cardiol Sin       Date:  2021-09       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.